论文部分内容阅读
目的:观察孟鲁司特对哮喘患者外周血NF-kB活性、IL-10水平及气道反应性的作用。方法:对40例哮喘患者(治疗组)在常规治疗的基础上加用孟鲁司特治疗3个月。观察治疗前后外周血NF-kB活性,血浆IL-10、IgE的水平和嗜酸性粒细胞(EOS)计数的变化,并进行气道反应性测定。并以30例同期入选的健康体检者作对照(对照组)。结果:治疗组患者治疗前外周血NF-KB活性、血浆IgE水平和EOS细胞数高于对照组,血浆IL-10水平低于对照组,治疗后外周血NF-KB活性、血浆IgE水平和EOS细胞数降低,IL-10水平上升。同时气道对组胺的反应阈值Dmin提高,对组胺的反应性Rrsc降低。结论:孟鲁司特治疗哮喘的作用机制可能是通过上调IL-10水平,降低NF-kB活性,从而抑制EOS聚集,达到治疗哮喘的目的。
Objective: To observe the effect of montelukast on the activity of NF-κB, IL-10 and airway responsiveness in peripheral blood of asthmatic patients. Methods: Forty asthmatic patients (treatment group) were treated with montelukast for 3 months on the basis of routine treatment. The changes of NF-κB activity, plasma IL-10, IgE levels and eosinophil count in peripheral blood were observed before and after treatment, and airway reactivity was measured. 30 healthy controls were enrolled in the same period (control group). Results: Before treatment, the levels of NF-κB, IgE and EOS in peripheral blood of patients in treatment group were higher than those in control group. The levels of IL-10 in plasma were lower in treatment group than those in control group. The levels of NF-κB, IgE and EOS The number of cells is decreased and the level of IL-10 is increased. At the same time, the response threshold of airway to histamine increased, and the reactivity to histamine decreased. Conclusion: The mechanism of montelukast in the treatment of asthma may be through the upregulation of IL-10 and decrease of NF-κB activity, thereby inhibiting the aggregation of EOS and achieving the purpose of treating asthma.